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ABSTRACT
Introduction: Neuropathic pain is a complex,
chronic pain state that is usually accompanied
by tissue injury. With neuropathic pain, the
nerve fibers themselves may be damaged,
dysfunctional, or injured.
Methods: A series of pharmacophoric hybrids of
substituted aryl semicarbazides incorporated
into a fused triazolo-thiadiazole nucleus were
synthesized and evaluated for neuropathic pain
activity. After the assessment of neurotoxicity and
peripheral analgesic activity, the compounds were
evaluated in two peripheral neuropathic pain
models, the chronic constriction injury and
partial sciatic nerve ligation, to assess their
antiallodynic and antihyperalgesic potential.
Results: Selected compounds exhibiting
promising efficacies (4b, 6a, and 7e) revealed
median effective dose (ED50) values ranging from
7.62–28.71 mg/kg in four behavioral assays of
allodynia and hyperalgesia (spontaneous pain,
tactile allodynia, cold allodynia, and mechanical
hyperalgesia). Studies carried out to assess
the underlying mechanism revealed that
compounds suppressed the inflammatory
component of the neuropathic pain by
inhibiting tumor necrosis factor (TNF)-alpha
and preventing oxidative and nitrosative stress.
Conclusion: Using a hybrid design approach,
the present study identified novel chemical
compounds that could be a potential lead for
the treatment of neuropathic pain.
Keywords: 2-Diphenyl-1-picrylhydrazyl;
Antiallodynic; Antihyperalgesic;
Neuropathic pain; Nitric oxide; TNF-alpha;
Triazolo-thiadiazole
INTRODUCTION
Neuropathic pain syndromes characterized by
neuronal hyperexcitability in damaged areas of
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the peripheral or central nervous system involve
complex pathophysiological processes [1]. The
development of inflammatorymicroenvironment
at the site of nerve injury and the release of
inflammatory mediators, together with their
coupled signaling pathways, contribute to the
generation and maintenance of neuropathic pain
[2, 3]. Following nerve injury, peripheral as well
as central sensitization occurs [4, 5] with
upregulation of tumor necrosis factor-alpha
(TNF-alpha), a pro-inflammatory cytokine, and
its receptors in Schwann cells, endothelial cells,
and in the dorsal horn of the spinal cord and
hippocampus [6–8]. TNF-alpha, a key mediator
in the inflammation, activates T cells and
macrophages, thereby initiating the innate
immune response. Consequently, the release of
other inflammatory cytokines, sympathomimetic
amines, prostaglandins, and nitric oxide (NO) is
stimulated, which are involved in sensitization of
primary afferent nociceptors [5–8]. Activated
microglia and pro-inflammatory cytokines also
induce the generation of free radicals leading to
oxidative and nitrosative stresses, which
exaggerate pain states [9, 10]. Inhibiting TNF
synthesis with thalidomide or treatment with
anti-TNF neutralizing antibodies at the time of
nerve injury blocks the development of
hyperalgesia and allodynia in neuropathic
animals [11, 12].
In recent years, the condensed bridgehead
nitrogen heterocyclic system of triazolo-
thiadiazole, which may be considered as the
cyclic analog of thiosemicarbazide and
biguanide has received considerable attention.
A wide spectrum of biological activities,
specifically anticonvulsant [13], analgesic [14],
anxiolytic [15], and anti-inflammatory [16]
properties has been reported for triazolo-
thiadiazole in the literature. The 1,2,4-triazole
core of the above fused system has gained
considerable attention regarding its action
against neuropathic pain acting through
various targets. Many triazole-based P2X7
antagonists [17, 18] sodium channel blockers
[19], and r-receptor inhibitors [20] have been
reported. The literature also reveals many
1,2,4-triazole-based cannabinoid modulators
[21, 22] possessing antinociceptive efficacies.
The primary focus of our research has been
on the design and synthesis of pharmacophoric
hybrids of aryl semicarbazones to develop
multifunctional leads useful in the treatment
of neurological disorders such as epilepsy
and neuropathic pain [23–26]. We have
previously reported the cyclization of various
aryl semicarbazones to 1,2,4-triazoles, which
resulted in improved anticonvulsant activities
[27]. Moreover, the literature reveals that
acylthiosemicarbazides and their corresponding
cyclized 1,3,4-thiadiazole derivatives possess
anti-inflammatory [28, 29] and analgesic [30]
activities.
In view of the above reports, the design
and synthesis of pharmacophoric hybrids of
aryl semicarbazides into triazolo-thiadiazole
templates was accomplished followed by
assessment of their antinociceptive potential and
underlying mechanism of action. Various reports
on the antinociceptive efficacy of 4-aminobutyric
acid (GABA) and gabapentin [31] and our research
on N-spiro GABA derivatives [32] prompted us to
explore the structure–activity relationships of





Melting points were measured in open capillary
tubes on a Buchi 530 melting point apparatus
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(Buchi, Flawil, Switzerland) and are
uncorrected. Proton nuclear magnetic
resonance (1H-NMR) spectra were recorded for
the compounds on a Bruker Avance (300 MHz)
HMR machine (Bruker, Fa¨llanden, Switzerland).
Chemical shifts are reported in parts per million
(ppm) using tetramethyl silane (TMS) as
an internal standard. Mass spectra were
measured with a Shimadzu GC–MS-QP5000
spectrophotometer. Elemental analyses (C, H,
and N) were undertaken with a Perkin-Elmer
model 240C analyzer, and all analyses were
consistent with theoretical values (within
±0.4%) unless indicated. The homogeneity of
the compounds was monitored by ascending
thin-layer chromatography (TLC) on silicagel-G
(Merck, Darmstadt, Germany) coated
aluminum plates, visualized by iodine vapor
and UV light.
General Scheme for the Synthesis of Potassium
Dithiocarbazinate (2a–2e)
Substituted phenyl semicarbazide, 1a–1e
(0.083 mol) was added to a solution of
potassium hydroxide (0.125 mol) in methanol
(50 mL) at 0–5C under stirring. To this, carbon
disulfide (0.025 mol) was added dropwise with
constant stirring. The reaction mixture was
stirred continuously for 12 h at room
temperature. The precipitated potassium
dithiocarbazinate salt was filtered, washed
with anhydrous ether, and dried in a vacuum.
The potassium salt thus obtained was used in
the next step without further purification.
General Scheme for the Synthesis of 4-Amino-
5-substituted-3-mercapto-(4H)-1,2,4-triazoles
(3a–3e)
Potassium dithiocarbazinate derivatives, 2a–2e
(0.02 mol) and hydrazine hydrate (99%,
0.04 mol) in water (25 mL) were refluxed for
10–15 h with occasional shaking. The reaction
mixture was cooled to room temperature
and diluted with cold water (10 mL). On
acidification with dilute hydrochloric acid
(HCl), a white precipitate resulted, which was
filtered, washed with cold water, dried, and
recrystallized from ethanol.
General Scheme for the Synthesis
of 3,6-Disubstituted-[1, 2, 4]-triazolo-[3,4-b]-
1,3,4-thiadiazoles (4a–43e, 5a–5e, 6a–6e,
7a–7e, 8a–8e)
An equimolar mixture (0.01 mol) of 4-amino-5-
substituted-3-mercapto-(4H)-1,2,4-triazoles (3a–
3e) and aromatic acids in phosphorous
oxychloride (10 mL) were refluxed for 5 h.
After the completion of the reaction, the
reaction mixture was slowly poured into
crushed ice with vigorous stirring and
neutralized with sodium bicarbonate
(NaHCO3). The precipitated solid was filtered,





Yield: 64%; melting point (m.p.): 185C; 1H
NMR (DMSO-d6) d: 2.01 (p, 2H), 2.63 (t, 2H),
2.84 (t, 2H), 4.78 (br s, 2H, D2O exchangeable),
6.91 (d, 2H), 7.13 (d, 2H), 8.24 (br s, NH, D2O
exchangeable), 13C NMR d 34.3, 41.8, 117.2,
119.4, 134.6, 139.2, 159.8, 168.8, 169.1: MS (ESI)




Yield: 72%; m.p.: 192C; 1H NMR (DMSO-d6) d:
2.03 (p, 2H), 2.66 (t, 2H), 2.83 (t, 2H), 4.72 (br s,
2H, D2O exchangeable), 7.01 (d, 2H), 7.22 (d,
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2H), 8.63 (br s, NH, D2O exchangeable),
13C
NMR d 34.2, 41.6, 122.2, 127.4, 129.6, 137.2,
157.8, 167.6, 168.2: MS (ESI) 295.05 (MH)?.
Anal. C11H11ClN6S (C, H, N).
6-(2-Aminoethyl)-N-(2,4-dimethylphenyl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (4c)
Yield: 71%; m.p.: 178C; 1H NMR (DMSO-d6) d:
2.02 (p, 2H), 2.14 (s, 3H), 2.37 (s, 3H), 2.68
(t, 2H), 2.84 (t, 2H), 4.84 (br s, 2H, D2O
exchangeable), 6.57 (d, 1H), 6.87–6.91
(m, 2H), 9.10 (br s, NH, D2O exchangeable),
13C NMR d 17.2, 21.6, 34.1, 41.6, 116.3, 126.3,
128.1, 132.1, 137.2, 139.4, 157.3, 167.1, 168.2:
MS (ESI) 289.12 (MH)?. Anal. C13H16N6S
(C, H, N).
6-(2-Aminoethyl)-N-(2,5-dimethylphenyl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (4d)
Yield: 68%; m.p.: 152C; 1H NMR (DMSO-d6)
d: 2.04 (p, 2H), 2.13 (s, 6H), 2.38 (s, 3H), 2.66
(t, 2H), 2.86 (t, 2H), 4.59 (br s, 2H, D2O
exchangeable), 6.67–6.69 (m, 2H), 6.94 (d, 1H),
9.10 (br s, NH, D2O exchangeable),
13C NMR d
17.2, 21.6, 34.1, 41.6, 115.3, 118.2, 126.1, 129.2,
136.1, 141.2, 157.2, 167.1, 168.1: MS (ESI)
289.12 (MH)?. Anal. C13H16N6S (C, H, N).
6-(2-Aminoethyl)-N-(2,6-dimethylphenyl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (4e)
Yield: 61%; m.p.: 144C; 1H NMR (DMSO-d6)
d: 2.01 (p, 2H), 2.14 (s, 6H), 2.66 (t, 2H), 2.88
(t, 2H), 4.71 (br s, 2H, D2O exchangeable), 6.69 (t,
1H), 6.96 (d, 2H), 9.41 (br s, NH, D2O
exchangeable), 13C NMR d 17.8, 34.1, 41.6,
121.4, 128.2, 136.4, 139.2, 157.1, 167.2, 168.3:




Yield: 69%; m.p.: 157C; 1H NMR (DMSO-d6) d:
0.93–1.10 (t, 6H), 1.35–1.40 (m, 4H), 1.56–1.62
(q, 4H), 2.66–2.68 (t, 1H), 6.94 (d, 2H), 7.16
(d, 2H), 8.43 (br s, 1H, D2O exchangeable),
13C
NMR d 14.2, 20.3, 38.3, 116.1, 118.2, 132.3,
137.2, 157.2, 167.2, 168.1: MS (ESI) 394.06




Yield: 78%; m.p.: 171C; 1H NMR (DMSO-d6) d:
0.96–1.11 (t, 6H), 1.37–1.41 (m, 4H), 1.54–1.59
(q, 4H), 2.65–2.67 (t, 1H), 7.04 (d, 2H), 7.25
(d, 2H), 8.81 (br s, 1H, D2O exchangeable),
13C
NMR d 14.2, 20.3, 38.3, 122.7, 127.1, 129.5,
137.1, 157.2, 167.3, 168.2: MS (ESI) 350.11
(MH)?. Anal. C16H20ClN5S (C, H, N).
N-(2,4-Dimethylphenyl)-6-(heptan-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (5c)
Yield: 73%; m.p.: 153C; 1H NMR (DMSO-d6) d:
0.97–1.11 (t, 6H), 1.36–1.42 (m, 4H), 1.55–1.60
(q, 4H), 2.14 (s, 3H), 2.37 (s, 3H), 2.66–2.69
(t, 1H), 6.59 (d, 1H), 6.87–6.92 (m, 2H), 9.40 (br
s, 1H, D2O exchangeable),
13C NMR d 14.2,
17.3, 20.3, 21.1, 38.3, 116.3, 126.3, 128.2,
131.2, 137.2, 139.3, 157.3, 167.4, 168.1: MS
(ESI) 344.19 (MH)?. Anal. C18H25N5S (C, H, N).
N-(2,5-Dimethylphenyl)-6-(heptan-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (5d)
Yield: 75%; m.p.: 138C; 1H NMR (DMSO-d6) d:
0.96–1.12 (t, 6H), 1.36–1.41 (m, 4H), 1.54–1.60
(q, 4H), 2.13 (s, 3H), 2.36 (s, 3H), 2.67–2.69
(t, 1H), 6.57–6.61 (m, 2H), 6.91 (d, 1H), 8.89 (br
s, 1H, D2O exchangeable),
13C NMR d 14.2,
Page 4 of 17 Pain Ther (2012) 1:3
123
17.3, 20.3, 21.1, 38.3, 115.2, 118.3, 126.1,
129.2, 136.2, 141.2, 157.3, 167.3, 168.1: MS
(ESI) 344.19 (MH)?. Anal. C18H25N5S (C, H, N).
N-(2,6-Dimethylphenyl)-6-(heptan-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (5e)
Yield: 80%; m.p.: 129C; 1H NMR (DMSO-d6) d:
0.95–1.12 (t, 6H), 1.36–1.42 (m, 4H), 1.56–1.61
(q, 4H), 2.15 (s, 6H), 2.64–2.67 (t, 1H), 6.67
(t, 1H), 6.98 (d, 2H), 9.41 (br s, 1H, D2O
exchangeable), 13C NMR d 14.2, 17.3, 20.3,
38.3, 121.1, 128.3, 136.2, 137.5, 157.2, 167.2,
168.1: MS (ESI) 344.18 (MH)?. Anal. C18H25N5S
(C, H, N).
N-(4-Bromophenyl)-6-(pyridin-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (6a)
Yield: 81%; m.p.: 203C; 1H NMR (DMSO-d6) d:
6.94 (d, 2H), 7.13 (d, 2H), 7.89 (d, 2H), 8.45 (d,
2H), 8.91 (br s, 1H, D2O exchangeable,
13C NMR
d 116.3, 118.3, 121.2, 132.4, 137.1, 143.1, 143.6,
149.2, 157.3, 167.4: MS (ESI) 372.98 (MH)?.
Anal. C14H9BrN6S (C, H, N).
N-(4-chlorophenyl)-6-(pyridin-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (6b)
Yield: 65%; m.p.: 216C; 1H NMR (DMSO-d6) d:
7.02 (d, 2H), 7.23 (d, 2H), 7.90(d, 2H), 8.46 (d,
2H), 8.95 (br s, 1H, D2O exchangeable),
13C
NMR d 121.2, 122.1, 127.3, 129.2, 137.1, 143.1,
143.6, 149.2, 157.3, 167.4: MS (ESI) 329.03
(MH)?. Anal. C14H9ClN6S (C, H, N).
N-(2,4-Dimethylphenyl)-6-(pyridin-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (6c)
Yield: 62%; m.p.: 192C; 1H NMR (DMSO-d6) d:
2.14 (s, 3H), 2.36 (s, 3H), 6.58 (d, 1H), 6.88–6.94
(m, 2H), 7.91 (d, 2H), 8.54 (d, 2H), 9.12 (br s,
D2O exchangeable, 1H),
13C NMR d 17.3, 21.1,
116.3, 121.2, 126.1, 128.1, 131.3, 137.2, 139.3,
143.0, 143.5, 149.1, 157.1, 167.2: MS (ESI)
323.10 (MH)?. Anal. C16H14N6S (C, H, N).
N-(2,5-Dimethylphenyl)-6-(pyridin-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (6d)
Yield: 68%; m.p.: 183C; 1H NMR (DMSO-d6) d:
2.13 (s, 3H), 2.37 (s, 3H), 6.66–6.71 (m, 2H),
6.90 (d, 2H), 5.64 (br s, D2O exchangeable, 1H),
7.92 (d, 2H), 8.45 (d, 2H), 13C NMR d 17.3, 21.1,
115.2, 118.3, 121.4, 126.1, 129.2, 136.2, 141.2,
143.1, 143.6, 149.2, 157.2, 167.1: MS (ESI)
323.10 (MH)?. Anal. C16H14N6S (C, H, N).
N-(2,6-Dimethylphenyl)-6-(pyridin-4-yl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (6e)
Yield: 70%; m.p.: 161C; 1H NMR (DMSO-d6) d:
2.15 (s, 6H), 6.65 (t, 1H), 6.96 (d, 2H), 7.91 (d,
2H), 8.47 (d, 2H), 9.21 (br s, D2O exchangeable,
1H), 13C NMR d 17.3, 121.1, 128.3, 136.2, 137.5,
143.1, 143.4, 149.1, 157.3, 167.4: MS (ESI)
323.10 (MH)?. Anal. C16H14N6S (C, H, N).
N-(4-Bromophenyl)-6-(4-nitrophenyl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-
amine (7a)
Yield: 68%; m.p.: 199C; 1H NMR (DMSO-d6) d:
6.93 (d, 2H), 7.14 (d, 2H), 7.81 (d, 2H), 8.08 (d,
2H), 9.71 (br s, D2O exchangeable, 1H),
13C
NMR d 116.1, 118.2, 124.3, 128.1, 132.3, 137.1,
139.2, 143.2, 147.4, 157.3, 167.3: MS (ESI)
416.97 (MH)?. Anal. C15H9BrN6O2S (C, H, N).
N-(4-Chlorophenyl)-6-(4-nitrophenyl)-
[1, 2, 4]triazolo[3,4-b][1, 3, 4]thiadiazole-3-
amine (7b)
Yield: 69%; m.p.: 207C; 1H NMR (DMSO-d6) d:
7.01 (d, 2H), 7.25 (d, 2H), 7.83 (d, 2H), 8.10 (d,
2H), 9.12 (br s, D2O exchangeable, 1H),
13C
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NMR d 122.7, 124.3, 127.1, 128.1, 129.5, 137.1,
139.2, 143.2, 147.4, 157.0, 167.1: MS (ESI)
373.02 (MH)?. Anal. C15H9ClN6O2S (C, H, N).
N-(2,4-Dimethylphenyl)-6-(4-nitrophenyl)-[1,
2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-amine
(7c)
Yield: 77%; m.p.: 176C; 1H NMR (DMSO-d6) d:
2.13 (s, 3H), 2.34 (s, 3H), 6.56 (d, 1H), 6.87–6.92
(m, 2H) 7.81 (d, 2H), 8.10 (d, 2H), 8.76 (br s, D2O
exchangeable, 1H), 13C NMR d 17.3, 21.1, 116.3,
124.2, 126.1, 128.1, 128.6, 131.3, 137.2, 139.3,
139.4, 143.1, 147.1, 157.3, 167.1: MS (ESI)
367.09 (MH)?. Anal. C17H14N6O2S (C, H, N).
N-(2,5-Dimethylphenyl)-6-(4-nitrophenyl)-[1,
2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-amine
(7d)
Yield: 73%; m.p.: 162C; 1H NMR (DMSO-d6) d:
2.14 (s, 3H), 2.35 (s, 3H), 6.66–6.70 (m, 2H), 6.90
(d, 2H), 7.81 (d, 2H), 8.09 (d, 2H), 9.71 (br s, D2O
exchangeable, 1H), 13C NMR d 17.3, 21.1, 115.1,
118.2, 124.4, 126.3, 128.1, 129.0, 136.1, 139.6,
141.2, 143.1, 147.4, 157.1, 167.2: MS (ESI)
367.09 (MH)?. Anal. C17H14N6O2S (C, H, N).
N-(2,6-Dimethylphenyl)-6-(4-nitrophenyl)-[1,
2, 4]triazolo[3,4-b][1, 3, 4]thiadiazol-3-amine
(7e)
Yield: 71%; m.p.: 151C; 1H NMR (DMSO-d6) d:
2.16 (s, 6H), 6.65 (t, 1H), 6.96 (d, 2H), 7.82
(d, 2H), 8.03 (d, 2H), 9.65 (br s, D2O
exchangeable, 1H), d 17.3, 121.1, 124.4, 128.3,
136.2, 137.5, 139.2, 143.1, 147.4, 157.3, 167.3:





Yield: 80%; m.p.: 174C; 1H NMR (DMSO-d6) d:
1.42–1.53 (m, 10H), 2.08–2.17 (m, 6H), 2.91
(t, 2H), 3.01 (t, 2H), 6.92 (d, 2H), 7.13 (d, 2H),
9.32 (br s, D2O exchangeable, 1H),
13C NMR d
15.3, 20.4, 25.1, 26.2, 39.1, 41.2, 41.4, 116.1,
118.2, 132.3, 137.2, 157.1, 167.1, 168.2, 171.3:






Yield: 75%; m.p.: 183C; 1H NMR (DMSO-d6) d:
1.42–1.53 (m, 10H), 2.08–2.15 (m, 6H), 2.94
(t, 2H), 3.02 (t, 2H), 7.02 (d, 2H), 7.22 (d, 2H),
9.08 (br s, D2O exchangeable, 1H),
13C NMR d
15.3, 20.4, 25.1, 26.1, 39.3, 41.2, 41.3, 122.0,
127.4, 129.1, 137.2, 157.0, 167.4, 168.1, 171.3:





Yield: 74%; m.p.: 159C; 1H NMR (DMSO-d6) d:
1.43–1.54 (m, 10H), 2.09–2.17 (m, 9H), 2.35
(t, 3H), 2.92 (t, 2H), 3.02 (t, 2H), 6.59 (d, 1H),
6.88–6.93 (m, 2H), 9.63 (br s, D2O
exchangeable, 1H), 13C NMR d 15.1, 17.5,
20.1, 21.2, 25.3, 26.1, 39.2, 41.1, 41.4, 116.1,
126.2, 128.2, 131.3, 137.1, 139.3, 157.1, 167.2,
168.1, 171.4: MS (ESI) 467.21 (MH)?. Anal.





Yield: 75%; m.p.: 141C; 1H NMR (DMSO-d6) d:
1.43–1.53 (m, 10H), 2.08–2.15 (m, 9H), 2.35
(s, 3H), 2.91 (t, 2H), 3.03 (t, 2H), 6.65–6.69
(m, 2H), 6.89 (d, 2H), 9.64 (br s, D2O
exchangeable, 1H), 13C NMR d 15.3, 17.4,
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20.3, 21.1, 25.1, 26.2, 39.1, 41.2, 41.4, 115.1,
118.2, 126.1, 129.2, 136.3, 141.1, 157.3, 167.1,
168.2, 171.2: MS (ESI) 467.21 (MH)?. Anal.




Yield: 72%; m.p.: 124C; 1H NMR (DMSO-d6)
d: 1.42–1.54 (m, 10H), 2.07–2.17 (m, 6H), 2.25
(s, 6H), 2.93 (t, 2H), 3.02 (t, 2H), 6.66 (t, 1H),
6.97 (d, 2H), 9.62 (br s, D2O exchangeable, 1H),
13C NMR d 15.1, 17.3, 20.1, 25.1, 26.1, 39.2,
41.1, 41.5, 121.2, 128.2, 129.1, 136.4, 137.2,
157.2, 167.2, 168.1, 171.1: MS (ESI) 467.21
(MH)?. Anal. C24H30N6O2S (C, H, N).
Pharmacology
Swiss albino mice (either sex) with weights
ranging from 20–25 g were used for the
assessment of neurotoxicity, acetic acid-induced
writhing, and formalin-induced flinching
model. Wistar rats of either sex (200–250 g)
were used for the inflammatory and
neuropathic pain models. All experiments were
approved by the Institutional Animal Ethics
Committee. Animals were housed six (mice)
and four (rats) per cage at constant temperature
under a 12 h light/dark cycle (lights on at 7:00
AM), with food and water ad libitum.
Motor Impairment
Minimal motor impairment was measured in
mice by the rotarod test. The mice were trained
to stay on an accelerating rotarod that rotates at
10 revolutions per minute. The rod diameter
was 3.2 cm. Neurotoxicity was indicated by the
inability of the animal to maintain equilibrium
on the rod for at least 1 min in each of the three
trials [33].
Acetic Acid-Induced Writhing
Writhing was induced in a group of mice by an
intraperitoneal injection of 0.1 mL of 2% (v/v)
acetic acid. Test group mice received acetic
acid 30 min after the administration of test
compounds. The number of writhings occurring
for a period of 30 min was recorded. For scoring
purposes, a writhe was indicated by stretching
of the abdomen with simultaneous stretching of
at least one hind limb. The percentage
inhibition of the writhing response was
calculated [34].
Formalin-Induced Flinching
The test involved intraplantar injection of 25 lL
of 1% formalin into the hind paw of mice,
which resulted in flinches in the paw in the
early phase (0–5 min) and the late phase
(10–30 min) [35]. Time spent in paw licking
and biting was monitored in each 5 min and
calculated for both the phases. Test compounds
were administered 30 min before the
experiment.
Unilateral Mononeuropathy:
Chronic Constriction Nerve Injury Model
Unilateral mononeuropathy was produced in
rats using the chronic constriction injury (CCI)
model performed essentially as described by
Bennett and Xie [36]. The rats were anesthetized
with an intraperitoneal dose of ketamine
(55 mg/kg) and xylazine (5 mg/kg) with
additional doses of the anesthetic given as
needed. Under aseptic conditions, a 3 cm
incision was made on the lateral aspect of the
left hind limb at the mid-thigh level. The left
paraspinal muscles were then separated from
the spinous processes and the common left
sciatic nerve was exposed just above the
trifurcation point. Four loose ligatures were
made with a 4-0 braided silk suture around the
sciatic nerve with about 1-mm spacing. The
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wound was then closed by suturing the muscle
using chromic catgut with a continuous suture
pattern. Finally, the skin was closed using silk
thread with horizontal-mattress suture pattern.
Induction of Peripheral Mononeuropathy:
Partial Sciatic Nerve Ligation Model
As described by Seltzer et al. [37], in
anesthetized rats, the left sciatic nerve was
exposed at mid-thigh level through a small
incision, cleared of adhering muscle tissue, and
one-half of the nerve thickness was tightly
ligated using 7.0 silk suture. The wound was
closed and dusted with neomycin powder. The
animals were then transferred to their home
cages and left for recovery.
Sensory Testing Using Nociceptive Assays
Compounds (100 mg/kg, i.p.) were
administered at t = 0, in 30% (v/v) PEG 400.
The control group of rats received only the
vehicle. Gabapentin (100 mg/kg, i.p.) was used
as a positive control. Paw withdrawal duration
(PWD) was assessed in spontaneous pain and
cold allodynia, and paw withdrawal threshold
(PWT) was assessed in tactile allodynia and
mechanical hyperalgesia. Percentage reversal in
spontaneous pain, allodynia, or hyperalgesia
was calculated for each animal as defined below
[38],
%Reversal
¼ post-dose value  pre-dose valueð Þ
contralateral paw value  pre-dose valueð Þ  100
Carrageenan-Induced Paw Edema
and Quantification of TNF-alpha
Paw edema was induced in Wistar rats by intra-
plantar injection of 50 ll of 2% carrageenan (k-
carrageenan, type IV, Sigma-Aldrich Company
Ltd, Dorset, UK) diluted in saline. The volume
of the paw edema (mL) was determined at 0, 60,
120, and 180 min using a water
plethysmometer (Ugo Basile, Varese, Italy).
Indomethacin (10 mg/kg, i.p.) was used as a
positive control [39]. The percentage protection
against inflammation was calculated as:
Vc - Vd/Vc 9 100, where Vc is the increase in
paw volume in the absence of the test
compound (control) and Vd is the increase of
paw volume after administration of the test
compound.
For the measurement of TNF-alpha, whole
right hind paws were collected at the third hour
after carrageenan injection. After rinsing with
ice-cold normal saline, they were homogenized
at 4C, and the homogenate was centrifuged at
12,000 rpm for 5 min. The supernatant obtained
was assayed using a TNF-alpha enzyme-linked
immunosorbant assay (ELISA) kit [40].
Estimation of Total Nitrite/Nitrate
On day 9 post-CCI, after 2 h of administration
of test compounds, the total nitrate/nitrite in
the brain and sciatic nerve was estimated
according to the reported procedure [9]. The
method involved reduction of nitrate to nitrite
followed by calorimetric estimation using
Griess’s reagent. The concentration of nitrite
in the supernatant was calculated using a
standard curve and expressed as a percentage
of the control.
2,2-Diphenyl-1-picrylhydrazyl Assay
A solution of 2,2-diphenyl-1-picrylhydrazyl
(DPPH) was prepared by dissolving 5 mg DPPH
in 2 mL methanol, and the solution was kept in
the dark at 4C. Varying concentrations of test
compounds (200 lL) were taken in a 96-well
microplate. Then, 5 lL methanolic DPPH
solution (final concentration 300 lM) was
added to each well. After 20 min incubation,
absorbance of the solution was read using an
ELISA plate reader (EL340 Biokinetic reader,
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Bio-Tek Instrumentation, CA, USA) at a
wavelength of 517 nm. A methanolic solution
of DPPH served as a control. A dose–response
curve was plotted to determine the half
maximal inhibitory concentration (IC50)
values. All tests and analyses were run in
triplicate and averaged [41]. Percentage
scavenging was calculated according to the
following equation.
% Scavenging




With the aim of synthesizing pharmacophoric
hybrids of chemical entities with proven
antinociceptive properties, the synthesis of
various substituted phenyl semicarbazides
(1a–1e), was accomplished from substituted
anilines via urea formation as per our
previously reported procedure [26]. Upon
treatment with carbon disulfide in the
presence of potassium hydroxide in ethanol,
substituted phenyl semicarbazides gave
the potassium salt of the corresponding
4-dithiocarbamate derivatives (2a–2e), which
underwent ring closure with an excess of
hydrazine hydrate to give 4-amino-3-
substituted-5-mercapto-(4H)-1,2,4-triazoles
(3a–3e). Resultant triazoles were further
converted to 1,2,4-triazolo-[3,4-b]-1,3,4-
thiadiazoles (4a–4e, 5a–5e, 6a–6e, 7a–7e,
8a–8e) via a one-pot reaction by condensation
with various acids in the presence of
phosphorous oxychloride as outlined in Fig. 1.
The synthesis of N-spiro GABA (8a–8e) was
accomplished as reported in our earlier work
[32]. The structures of the synthesized
compounds were characterized by both
spectral and elemental analysis, and the data
were within ±0.4% of the theoretical values.
Following assessment of neurotoxicity of the
synthesized compounds by rotarod (data not
shown), the non-neurotoxic compounds were
further evaluated in acetic acid-induced
writhing and formalin-induced flinching
models (Table 1). The acetic acid-induced
writhing model is a chemical pain test used to
evaluate acute antinociceptive function,
whereas the formalin model is a tonic
inflammatory pain model used to distinguish
peripherally and centrally acting compounds. It
is characterized by two phases: first phase
(0–5 min) occurs due to direct stimulation of
nociceptors (C-fibers), whereas the second
phase (10–30 min) results following the
development of a localized inflammatory
response along with activation of N-methyl-D-
aspartate (NMDA) and non-NMDA receptors
and nitric oxide production [42, 43]. All tested
compounds, except 6e, suppressed the acetic
acid-induced writhing response significantly
(P\0.01) in comparison with the control
(Table 1). The standard drug, indomethacin,
exhibited the highest percentage inhibition
(96.1%). In the formalin-induced flinching
model, all of the compounds showed
significant suppression in both phases, with
the exception of compounds 4a, 4d, 6d, 6e, 7c,
and 8d, which were effective only in the second
phase of the formalin assay. Indomethacin
(72.1%) significantly reversed flinching
responses in the second phase of the formalin
assay. The triazolo-thiadiazoles were further
evaluated in two well-established peripheral
neuropathic pain models: the CCI and the
partial sciatic nerve ligation (PSNL) model. In
the CCI model, the left sciatic nerve proximal to
the trifurcation point was constricted with four
loose ligatures using 4-0 braided silk thread [36].
In the PSNL model, left sciatic nerve was
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exposed at mid-thigh level and one-half of the
nerve thickness was tightly ligated using 7.0 silk
sutures [37]. Four nociceptive assays with the
aim of determining the severity of behavioral
neuropathic responses, namely allodynia and
hyperalgesia, were performed. The assays
involved measurement of the degree of
spontaneous (ongoing) pain and tests of
hind limb withdrawal to cold and mechanical
stimuli (tactile allodynia, cold allodynia, and
mechanical hyperalgesia). A minimum of
10 min separated the testing procedures to
reduce the influence of prior nociceptive
testing. All animals included in the study
showed altered sensory responses in all the
four behavioral nociceptive tests, 9 days
post-surgery. The sham-operated animals
showed no significant difference from the
preoperative baseline sensory response values.
Percentage reversal in spontaneous pain, tactile
allodynia, cold allodynia, and mechanical
hyperalgesia was assessed day 9 post-surgery.
In the CCI model (Fig. 2), compounds 4b,
6a, and 7e completely reversed the
spontaneous pain response throughout the
time period of testing (0.5–2.0 h) similar to
gabapentin. Compounds 7a and 8b were
effective only up to 0.5 h, whereas
compounds 4a, 4e, 7b, and 8e were effective
up to 1 h. The onset of action of compound 7c
was at 1 h. Other compounds were ineffective
in this test. Three compounds, 4b, 6a, and 7e,
were effective in attenuating the tactile
allodynia throughout the 2 h experiment
similar to gabapentin. Compound 4a was
effective only up to 0.5 h of the experiment
whereas compounds 4e, 8b, and 8e were
effective up to 1 h. All other compounds were
ineffective in this test. In the cold allodynia
produced in CCI rats, significant reversal of
paw withdrawal durations was observed at
all timepoints by the administration of
compounds 4b and 7e. Gabapentin was also





















































Fig. 1 Synthetic route to substituted triazolo-thiadiazoles
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Compound 6b was effective only up to 0.5 h
whereas compounds 4a, 6a, 7c, 8c, and 8e were
effective up to 1 h of the experiment.
Mechanical hyperalgesia was significantly
attenuated at all the timepoints by 4b and 6a
similar to gabapentin. Compounds 7b and 8e
were effective only up to 0.5 h, whereas
compounds 4e, 5a, 7e, and 8c were effective
until 1 h. Compound 6c exhibited irregular
activity pattern.
Overall, it appears that in the CCI model of
neuropathic pain compounds that showed
promising results include 4b, 6a, 7e, and 8e,
which were effective in four tests; 4a and 4e,
effective in three tests; and 7b, 7c, 8b, and 8c,
effective in two tests.
In the PSNL model (Fig. 3), the paw
withdrawal durations due to spontaneous
ongoing pain were significantly reduced by
compounds 4b, 6a, and 7e throughout the
experiment, similar to gabapentin. The
compounds 7c and 8e were effective up to
0.5 h of the experiment, whereas compounds
4a, 4e, and 8b exhibited activity up to 1 h. The
tactile allodynia produced in the PSNL model
was effectively reversed by compounds 4b and
6a at all the timepoints, similar to gabapentin.
Compound 4a was effective only up to 0.5 h of
the experiment, whereas compounds 4e, 7e, 8b,
8c, and 8e were effective up to 1 h of the
experiment. The onset of action for compound
6b was at 1 h. Cold allodynia produced in the
PSNL model was completely reversed by
compounds 4b, 6a, and 7e. Compounds 6b
and 6d were effective only up to 0.5 h of the
experiment, whereas compounds 4a, 4e, 6c, 8c,
and 8e were effective up to 1 h of the
experiment. Compounds 4b, 7b, and 7e
significantly reversed mechanical hyperalgesia
at all the timepoints, similar to gabapentin.
Compounds 6a, 7a, and 8c were effective in first
1 h of the experiment. Compound 7c exhibited









Phase I Phase II
Control – – –
4a 93.6* 13.4 68.5*
4b 91.3* 65.5* 90.9*
4c 67.9* 45.2* 69.8*
4d 48.2* 13.4 56.3*
4e 79.3* 43.4* 62.4*
5a 64.6* 41.5* 76.8*
5b 67.9* 47.9* 87.9*
5c 50.9* 47.7* 86.4*
5d 62.2* 43.8* 63.4*
5e 90.2* 50.5* 85.7*
6a 94.0* 63.4* 84.1*
6b 56.6* 73.2* 62.1*
6c 46.2* 65.3* 67.9*
6d 48.2* 23.4 62.3*
6e 25.5 10.9 66.6*
7a 53.8* 40.4* 89.9*
7b 57.5* 56.0* 71.7*
7c 69.8* 22.6 53.6*
7d 58.5* 47.9* 91.5*
7e 92.6* 52.3* 93.5*
8a 51.9* 63.5* 58.3*
8b 62.2* 63.1* 68.1*
8c 68.0* 61.3* 71.0*
8d 44.3* 15.2 60.6*
8e 76.4* 49.1* 74.7*
Indomethacina 96.1 4.35 72.1*
Vehicle treated animals received 30% (v/v) PEG 400 in
water
* Represents signiﬁcance at P\0.05 compared to the
vehicle (one way analysis of variance [ANOVA], followed
by Dunnet Test, n = 4) at a dose of 100 mg/kg
a Indomethacin was taken as a positive control at 5 mg/kg
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irregular activity. Overall, it appears, in the
PSNL model, compounds that exhibited
promising results included 4b, 6a, and 7e,
which were effective in four tests; 4a, 4e, and
8a, effective in three tests; and 6b, 7c, 8b, and
8c, effective in two tests.
Compounds exhibiting more than 90%
reversal in one or more of the nociceptive assays
(4b, 6a, and 7e) were taken further for ED50 studies
(Table 2). In the CCI model, compound 6a
reversed spontaneous pain with an ED50 value of
13.92 mg/kg at 0.5 h. Compound 4b reversed
tactile and cold allodynia with an ED50 value of
7.62 and 16.92 mg/kg at 0.5 and 1 h, respectively.
Compound 7e reversed mechanical hyperalgesia
with an ED50 value of 12.94 mg/kg at 0.5 h. In the
PSNL model, compound 4b reversed spontaneous
pain and tactile allodynia with an ED50 value of
14.91 and 13.95 mg/kg at 0.5 and 1 h,
respectively. In cold allodynia and mechanical
hyperalgesia, compound 6a was the most
effective compound with an ED50 value of 21.91
and 28.10 mg/kg at 0.5 and 1 h, respectively.
The significant reversal exhibited by most of
the test compounds in acetic acid-induced
writhing model supported their role as
peripherally acting analgesics. Significant
suppression of flinching observed in both the
phases of formalin assay (Table 1) suggested the
mediation of anti-inflammatory pathways.
The carrageenan-induced paw edema model
was used to investigate the probable role of
the selective compounds (4b, 6a, and 7e) in
the inhibition of inflammatory mediators.
A significant reduction in edema was observed
for compounds 4b, 6a, and 7e at all the
timepoints (Table 3). TNF-a levels quantified






































































































Fig. 2 Efﬁcacy of compounds in spontaneous pain (a),
tactile allodynia (b), cold allodynia (c), and mechanical
hyperalgesia (d) in chronic constriction injury rats. Each
value represents the percent reversal (mean ± SEM) in
spontaneous pain, tactile allodynia, cold allodynia, and
mechanical hyperalgesia of four rats. Asterisk denotes a
signiﬁcant value, in comparison to their respective vehicle
control at P\0.05 (one-way analysis of variance
[ANOVA], followed by post hoc Dunnet test)
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found to be inhibited by compounds 4b, 6a,
and 7e. As a result, there was inhibition of
keratinocyte chemokines (KC), leading to
subsequent inhibition of interleukin-1beta,
prostanoids, and sympathomimetic amines, as
evidenced by reduction of edema [44]. The
occurrence of nitrosative stress following nerve







































































































Fig. 3 Efﬁcacy of compounds in spontaneous pain (a),
tactile allodynia (b), cold allodynia (c), and mechanical
hyperalgesia (d) in partial sciatic nerve ligation rats. Each
value represents the percent reversal (mean ± SEM) in
spontaneous pain, tactile allodynia, cold allodynia, and
mechanical hyperalgesia of four rats. Asterisk denotes a
signiﬁcant value, in comparison to their respective vehicle
control at P\0.05 (one-way analysis of variance
[ANOVA], followed by post hoc Dunnet test)
Table 2 Median effective dose (ED50) studies of compounds 4b, 6a, and 7e
Treatment ED50 values (mg/kg) in CCI model
(TPE in min)a
ED50 values (mg/kg) in PSNL model
(TPE in min)a
SP TA CA MH SP TA CA MH
4b 17.01 (1.0) 7.62 (0.5) 16.92 (1.0) 14.62 (1.0) 14.91 (0.5) 13.95 (1.0) 28.07 (0.5) –
6a 13.92 (0.5) 8.92 (0.5) 28.71 (0.5) 13.45 (1.0) 18.51 (1.0) 19.53 (0.5) 21.91 (0.5) 28.10 (1.0)
7e 22.90 (1.0) 14.28 (0.5) 21.41 (1.0) 12.94 (0.5) 21.42 (1.0) 22.65 (1.0) – –
Each value represents median effective dose in SP, TA, CA, and MH
CA cold allodynia; CCI chronic constriction injury; MH mechanical hyperalgesia; PSNL partial sciatic nerve ligation; SP
spontaneous pain; TA tactile allodynia
a TPE represents time of peak effect in hours
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nitrite and nitrate levels in both the brains
and sciatic nerves of the rats, led us to
estimate the levels of nitrite, a metabolite of
nitrate in the brain and sciatic nerve of CCI rats
using Griess’s reagent. Also, the free-radical
scavenging activity of the compounds
was assessed spectrophotometrically via the
DPPH assay. No significant reduction of nitrite
in the brain of CCI rats was found when
compared to vehicle-treated animals for
compounds 4b, 6a, and 7e. However, a
significant reduction was observed in the
sciatic nerve of the CCI animals when
compared to the vehicle-treated group for 4b,
6a, and 7e. The results indicate the inhibition
of local NO at the site of nerve injury. The
compounds (4b, 6a, and 7e) were found to
exhibit free-radical scavenging abilities in the
Table 3 Percent protection in the edema and inhibition of tumor necrosis factor (TNF)-alpha in the carrageenan injected
paw by compounds 4b, 6a, and 7e
Treatment % Protection in carrageenan-induced paw edema % Inhibition of TNF-alphaa
60 min 120 min 180 min
Vehicle – – – –
4b 54.5 ± 2.3* 50.4 ± 2.6* 71.4 ± 3.4* 82.6 ± 2.8*
6a 43.3 ± 1.7* 62.6 ± 3.7* 77.2 ± 4.1* 88.8 ± 1.5*
7e 54.7 ± 3.7* 50.1 ± 2.1* 81.7 ± 2.3* 82.0 ± 3.1*
Indomethacinb 50.3 ± 2.6* 61.2 ± 3.8* 66.9 ± 4.2* –
* Represents signiﬁcance at P\0.05 compared to the vehicle (one way analysis of variance [ANOVA], followed by Dunnet
Test, n = 4)
a Percent inhibition of TNF-alpha in the paw of carrageenan-stimulated mice as compared to vehicle-treated controls
b Indomethacin was tested at the dose of 10 mg/kg i.p.
Table 4 2-Diphenyl-1-picrylhydrazyl (DPPH) scavenging activity and effect of compounds 4b, 6a, and 7e on nitrosative
stress




% Inhibition of nitrosative stress (nitrite)a
IC50 (lM) Brain Sciatic nerve
Vehicle – – – –
4b 82.6 ± 2.8* 190 19.4 ± 1.2 48.7 ± 1.8*
6a 88.8 ± 1.5* 201 24.4 ± 2.1 58.3 ± 2.3*
7e 82.0 ± 3.1* 209 22.3 ± 1.6 61.2 ± 3.1*
Indomethacinc – – – –
Asterisk denotes a signiﬁcant value, in comparison to their respective vehicle control at P\0.05 (one-way analysis of
variance [ANOVA], followed by post hoc Dunnet test)
TNF tumor necrosis factor
a Percent inhibition of nitric oxide in brain and sciatic nerve of chronic constriction injury rats. Compounds were tested at
the respective minimal ED50 dose administered i.p.
b DPPH radical scavenging activity of the test compounds (values are represented as % scavenging calculated from the
average of triplicate experiments)
c Indomethacin was tested at the dose of 10 mg/kg i.p.
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DPPH assay, thereby acting by reducing
oxidative stress (Table 4).
DISCUSSION
The results obtained in the nociceptive assays
provide an insight into the structure–activity
relationships of the triazolo-thiadiazoles.
Functionalization of the aryl ring of
the semicarbazide fragment forming
triazolo-thiadiazoles with dimethyl substitutions
resulted in variable antinociceptive efficacy.
Compounds having a 2,4-dimethyl substituted
aryl semicarbazide fragment (6c, 7c, and 8c)
reversed one or more nociceptive parameters in
both CCI and PSNL animals. Introduction of a
2,5-dimethyl substituted aryl ring proved to be
detrimental for the antinociceptive efficacy in
both CCI and PSNL animals. Only one
compound, 6d, was found to be effective against
cold allodynia in PSNL animals. The introduction
of electron-releasing 2,6-dimethyl substitutions
(4e, 7e, and 8e) resulted in significant attenuation
of one or more nociceptive parameters in
neuropathic animals. Introduction of an
electron-withdrawing halogen (bromo) para to
the aryl ring resulted in significant activity against
one or more nociceptive assays. Compounds 4a,
5a, 6a, and 7a were effective in CCI animals,
whereas compounds 4a, 6a, 7a, and 8a were found
to be effective in one or more nociceptive
parameters in PSNL animals. Compounds with
para chloro-substituted aryl rings (4b, 6b, 7b, and
8b) resulted in significant attenuation of one or
more nociceptive parameters in neuropathic
animals.
Accounting for the nociceptive efficacies
observed for triazolo-thiadiazoles in the
neuropathic pain models, it can be generalized
that unlike 2-propylpentanyl substitution at the
R2 position (5a–5e), 2-aminobutanyl
substitution (4a, 4b, and 4e) at the R2 position
was beneficial for nociceptive efficacy. Aryl
substitution with a 4-nitobenzyl group (6a–6d)
and heteroaryl substitution with an isonicotinyl
group (7a, 7b, 7c, and 7e) resulted in significant
attenuation of nociceptive parameters. N-spiro
GABA substitution (8a, 8b, 8c, and 8e) also
proved to be additive for antinociceptive
efficacy.
In conclusion, utilizing a pharmacophoric
hybrid approach, a series of structurally novel
triazolo-thiadiazoles derivatives were synthesized
and evaluated for acute antinociceptive,
antiallodynic, and antihyperalgesic potential. In
the carrageenan-induced paw edema model, in
which there is a pronounced local TNF-alpha
response, compounds 4b, 6a, and 7e significantly
inhibited paw swelling as well as localized
TNF-alpha levels in the paw, thereby
suppressing the inflammatory component of
neuropathic pain. The neuroprotection
exhibited by compounds 4b, 6a, and 7e is also
associated with their free-radical scavenging
abilities and subsequent attenuation of
oxidative and nitrosative stresses.
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